Anthem Biosciences Limited has informed the Exchange regarding a press release for the quarter and the financial year ended March 31, 2026.
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.4 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anthem Biosciences reported strong FY26 results with revenue of ₹21,243 Mn (up 15.2% YoY) and PAT of ₹5,918 Mn (up 31.1% YoY). EBITDA grew 30.8% to ₹9,896 Mn with margins expanding to 43.4% from approximately 40.7% in FY25. Q4FY26 was particularly strong with revenue of ₹6,109 Mn (up 26.4% YoY) and PAT of ₹1,898 Mn (up 129.8% YoY), marking the highest revenue quarter ever. EBITDA margins for Q4 stood at 48.1%. An exceptional item of ₹244 Mn was recognized due to the new Indian labour codes impact. CRDMO business contributed ₹17,727 Mn while Specialty Ingredients contributed ₹3,516 Mn to full-year revenue. The company maintains a net cash position of ₹13,743 Mn.
Strong financial performance with robust profit growth and margin expansion indicates operational efficiency gains. The 31% PAT growth and 43%+ EBITDA margins demonstrate strong execution, which should be positive for shareholders. The exceptional labour code charge is a one-time item and not expected to recur.